Compare SoFi Technologies Inc (SOFI) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SoFi Technologies Inc vs TransMedics Group Inc — how do they compare? SoFi Technologies Inc trades at $17.63 (market cap $21.82B), while TransMedics Group Inc trades at $74.3 (market cap $2.54B). The key difference: SoFi Technologies Inc is far larger — about 8.6× TransMedics Group Inc's market cap. Which is the better fit depends on your goals.
| SOFI | TMDX | |
|---|---|---|
Market Cap | $21.82B | $2.54B |
Sector | Financials | Technology |
52-Week High | $32.21 | $150.42 |
52-Week Low | $15.15 | $61.99 |
Enterprise Value | — | $2.94B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About SoFi Technologies Inc
SoFi is a financial services company that was founded in 2011 and is currently based in San Francisco. Initially known for its student loan refinancing business, the company has expanded its product offerings to include personal loans, credit cards, mortgages, investment accounts, banking services, and financial planning. The company intends to be a one-stop shop for its clients' finances and operates solely through its mobile app and website. Through its acquisition of Galileo in 2020 the company also offers payment and account services for debit cards and digital banking.
Read more on SOFI →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
